Press Releases

 
Press Releases
  Date Title View
Dec 23, 2015
WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration ("FDA") that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test fo...
Nov 30, 2015
WALTHAM, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3® Test, today announced an amendment to its license and distribution agreement for Galectin-3. Amendment to License and Distribution Agreement In support of the commercialization of automated testing for galectin-3, BG ...
Nov 17, 2015
WALTHAM, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three and nine months ended September 30, 2015. "Our operating results in the third quarter of 2015 reflect our ongoing efforts to extend our cash runway through the pruden...
Nov 11, 2015
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that the company will host a business update conference call and webcast on Tuesday, November 17, 2015, beginning at 8:30 a.m. Eastern Time. Conference Call Details The conference call may be accessed by dialing (877) 845-1016 from the U.S. and ...
Sep 15, 2015
WALTHAM, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today announced that on September 14, 2015, the Company was notified by The NASDAQ Stock Market LLC ("NASDAQ") that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on ...
Aug 14, 2015
Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S. Operating Cash Burn for Second Quarter of 2015 Reduced by 68% From Second Quarter of 2014 -- Company to Host Business Update Conference Call on Wednesday, August 19, 2015 -- WALTHAM, Mass., Aug. 14, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. ...
Aug 13, 2015
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3® Test, today announced the pricing of an underwritten public offering of its equity securities. Roth Capital Partners is acting as sole manager for the offering. The company is offering 2,315,654 Series A units, each c...
Aug 12, 2015
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the of...
Jul 27, 2015
WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT® automated immunoassay analyzer will be presented at the 2015 Ame...
Jul 15, 2015
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that it has paid off its secured term loan facility with General Electric Capital Corporation and Comerica Bank. The secured term loan in the aggregate principal amount of $10 million was funded ...
1
... NextLast
= add release to Briefcase